BCMA/TNFRSF17 Antibody (Vicky-2) - BSA Free

Novus Biologicals | Catalog # NBP1-97608

Novus Biologicals
100% Guarantee

Key Product Details

Species Reactivity

Mouse

Applications

Western Blot, Flow Cytometry, Immunoprecipitation

Label

Unconjugated

Antibody Source

Monoclonal Rat IgG2A Clone # Vicky-2

Format

BSA Free
View all BCMA/TNFRSF17 Primary Antibodies »

Product Specifications

Immunogen

Recombinant mouse BCMA extracellular domain (aa 1-46).

Reactivity Notes

Does not cross-react with Human BCMA.

Clonality

Monoclonal

Host

Rat

Isotype

IgG2A

Scientific Data Images for BCMA/TNFRSF17 Antibody (Vicky-2) - BSA Free

Western Blot: BCMA/TNFRSF17 Antibody (Vicky-2)BSA Free [NBP1-97608]

Western Blot: BCMA/TNFRSF17 Antibody (Vicky-2)BSA Free [NBP1-97608]

Western Blot: BCMA/TNFRSF17 Antibody (Vicky-2) [NBP1-97608] - Lane 1: MW marker, Lane 2: Mouse BCMA Recombinant Protein.

Applications for BCMA/TNFRSF17 Antibody (Vicky-2) - BSA Free

Application
Recommended Usage

Flow Cytometry

1:1000

Immunoprecipitation

1:200

Western Blot

1:1000

Flow Cytometry Panel Builder

Bio-Techne Knows Flow Cytometry

Save time and reduce costly mistakes by quickly finding compatible reagents using the Panel Builder Tool.

Advanced Features

  • Spectra Viewer - Custom analysis of spectra from multiple fluorochromes
  • Spillover Popups - Visualize the spectra of individual fluorochromes
  • Antigen Density Selector - Match fluorochrome brightness with antigen density
Build Your Panel Now
Flow Cytometry

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

PBS

Format

BSA Free

Preservative

0.02% Sodium Azide

Concentration

1.0 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: BCMA/TNFRSF17

B cell maturation antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a type III transmembrane glycoprotein that plays a role in B cell maturation and differentiation into plasma cells and is a therapeutic target for treatment of multiple myeloma (MM) (1,2). BMCA is synthesized as a protein of 184 amino acids (aa) in length with a theoretical molecular weight of 20.2 kDa consisting of an extracellular N-terminus containing 6 cysteine residues, a transmembrane domain, and an intracellular tumor necrosis factor (TRAF) binding domain (1). BCMA is functionally similar to two other TNFR superfamily members, B cell activation factor receptor (BAFF-R) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) (1,2). BCMA is primarily expressed on plasmablasts, plasma cells, and late-stage B cells (1,2).

BCMA has two agonistic ligands: BAFF and a proliferation-inducing ligand (APRIL) (1,2). APRIL has higher affinity for BCMA than BAFF and the binding is mediated by CD138/syndeclin-1 (2,3). Activation of BCMA promotes the growth and survival of plasma cells, or MM cells in disease, through several signaling pathways such as NFkappaB, MEK/ERK, AKT, JNK, and p38 (1,2). In MM cells the BCMA activation and downstream signaling cascade functions to upregulate antiapoptotic proteins including Bcl-2, Bcl-xL, and Mcl-1 and protect the cells against therapeutic agents like dexamethasone (2,3).

Given its specific expression on plasma cells but not memory B cells, naive B cells, or hematopoietic stem cells, BCMA has garnered much interest as a therapeutic target for the treatment of MM (1-4). Current BCMA-targeted immunotherapy strategies include antibody-drug conjugates (ADC), chimeric antigen receptor (CAR) T cells, bispecific T cell engager (BiTE), and bispecific/trispecific antibodies (1-4). CAR T cell therapy in particular has demonstrated promising clinical results (2,4). Still, more research needs to be done to improve the efficacy and risk of relapse following CAR T cell therapy and may also include targeting additional antigens in combination with BCMA or utilizing pharmacological agents to increase antigen density (4).

References

1. Yu, B., Jiang, T., & Liu, D. (2020). BCMA-targeted immunotherapy for multiple myeloma. Journal of hematology & oncology, 13(1), 125. https://doi.org/10.1186/s13045-020-00962-7

2. Cho, S. F., Anderson, K. C., & Tai, Y. T. (2018). Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Frontiers in immunology, 9, 1821. https://doi.org/10.3389/fimmu.2018.01821

3. Dalla Palma, B., Marchica, V., Catarozzo, M. T., Giuliani, N., & Accardi, F. (2020). Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma. Journal of clinical medicine, 9(9), 3022. https://doi.org/10.3390/jcm9093022

4. Mikkilineni, L., & Kochenderfer, J. N. (2021). CAR T cell therapies for patients with multiple myeloma. Nature reviews. Clinical oncology, 18(2), 71-84. https://doi.org/10.1038/s41571-020-0427-6

Long Name

B Cell Maturation Factor

Alternate Names

CD269, TNFRSF13A, TNFRSF17

Gene Symbol

TNFRSF17

Additional BCMA/TNFRSF17 Products

Product Documents for BCMA/TNFRSF17 Antibody (Vicky-2) - BSA Free

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Download SDS

Product Specific Notices for BCMA/TNFRSF17 Antibody (Vicky-2) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Citations for BCMA/TNFRSF17 Antibody (Vicky-2) - BSA Free

Customer Reviews for BCMA/TNFRSF17 Antibody (Vicky-2) - BSA Free

There are currently no reviews for this product. Be the first to review BCMA/TNFRSF17 Antibody (Vicky-2) - BSA Free and earn rewards!

Have you used BCMA/TNFRSF17 Antibody (Vicky-2) - BSA Free?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 for a review with an image

$10/€7/£6/$10CAN/¥1110 for a review without an image

Submit a review
Amazon Gift Card

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs for BCMA/TNFRSF17 Antibody (Vicky-2) - BSA Free

Showing  1 - 1 of 1 FAQ Showing All

  • Q: Is clone RM0336-17B1 suitable to be used for FACS as it is mentioned on biocompare.com?

    A:

    Looking at our internal records for BCMA Antibody (RM0336-17B1), catalog # NBP2-11939, I see that flow cytometry was once stated as a validated application for this antibody, but that flow was removed earlier in the year because after evaluation we concluded that there was not sufficient evidence to guarantee NBP2-11939 for flow. If you would like to use one of these antibodies in flow cytometry, therefore, I recommend that you choose BCMA Antibody (Vicky-2), catalog # NBP1-97608, as flow is stated as a validated application for this one. If you did want to test RM0336-17B1/NBP2-11939 in flow cytometry, you wouldn't be covered by our guarantee, but you would be eligible for our Innovator's Reward program.

Showing  1 - 1 of 1 FAQ Showing All
View all FAQs for Antibodies